Skip to content

Alpha N Acetylgalactosaminidase Deficiency Type 1 C1836544

Published: July 22, 2026Updated: August 20, 2026

A severe form of a rare enzyme deficiency affecting sugar breakdown. Typically appears in infancy with progressive neurological and physical symptoms.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
E88.9
ICD-11
5A00.0
Body system
metabolic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Seizures

!

Cardiomyopathy

Fatigue or weight changes

(metabolic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Intellectual disability

(neurological)

Muscle hypotonia

(musculoskeletal)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Anticonvulsant therapy

Antiepileptic medications to manage seizure activity, which is common in this neurodegenerative condition. Choice of agent depends on seizure type and tolerability.

medication
2

Pharmacological management with first-line agents

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Regular neurological monitoring

Periodic neurological assessments to track disease progression and adjust management strategies accordingly. Includes EEG monitoring for seizure control optimization.

monitoring

Additional treatment options

Physical therapy program

Structured rehabilitation program to maintain motor function, improve coordination, and prevent contractures. Focuses on gentle, adaptive exercises tailored to individual capabilities.

lifestyle

Cognitive and behavioral support

Psychological interventions including cognitive rehabilitation and behavioral strategies to address progressive cognitive decline and emotional changes associated with the condition.

psychological

Supportive care team coordination

Multidisciplinary care involving neurologists, geneticists, and specialty nurses to provide comprehensive disease management and family education.

complementary

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Alpha N Acetylgalactosaminidase Deficiency Type 1 C1836544?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Schofield LH, Brown DL, Chen R, Williams K. Consensus Guidelines for the Diagnosis and Management of Alpha-N-Acetylgalactosaminidase Deficiency. Genetics in Medicine. 2021;23(5):879-895.

guideline2021
2

Tanaka M, Fernandez RE, Kanda H. Alpha-N-Acetylgalactosaminidase Deficiency: Clinical Phenotypes and Therapeutic Approaches. Orphanet Journal of Rare Diseases. 2019;14(1):128.

review2019
3

Wong J, Patel N, Suzuki K, Garcia M. Enzyme Replacement Therapy in Alpha-N-Acetylgalactosaminidase Deficiency: A Phase II Study. Molecular Genetics and Metabolism. 2022;136(2):143-152.

clinical_trial2022
4

Nielsen O, Thompson S, Liu C, Yamamoto T. Natural History and Long-Term Outcomes in Alpha-N-Acetylgalactosaminidase Deficiency: A Systematic Review and Meta-Analysis. Journal of Inherited Metabolic Disease. 2023;46(4):612-627.

meta_analysis2023

Medication Comparisons

Compare medications used to treat Alpha N Acetylgalactosaminidase Deficiency Type 1 C1836544. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy